---
url: https://www.servicesaustralia.gov.au/eye-subfoveal-choroidal-neovascularisation
title: Eye - subfoveal choroidal neovascularisation - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:40:33.503Z
source: servicesaustralia.gov.au
---
# Eye - subfoveal choroidal neovascularisation

The PBS subsidises aflibercept, brolucizumab, faricimab and ranibizumab for patients with subfoveal choroidal neovascularisation.

## on this page

-   [Patient eligibility](#a1)
-   [Treatment specifics](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with aflibercept, brolucizumab, faricimab and ranibizumab under the _National Health Act 1953_, section 85 for patients with subfoveal choroidal neovascularisation.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing aflibercept, brolucizumab, faricimab and ranibizumab.

## Treatment specifics

To be eligible for PBS-subsidised treatment with these medicines, patients must be treated by either an:

-   ophthalmologist
-   accredited ophthalmology registrar in consultation with an ophthalmologist.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised aflibercept, brolucizumab, faricimab or ranibizumab to treat subfoveal choroidal neovascularisation can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [subfoveal choroidal neovascularisation - initial authority application form](/pb072?context=20)
-   relevant attachments.

Applications to move between different drugs to treat subfoveal choroidal neovascularisation will require a new initial authority application to be completed.

### Applying for continuing treatment

Continuing PBS-subsidised treatment with aflibercept, faricimab or ranibizumab is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

Applications for continuing authority approval to prescribe PBS-subsidised brolucizumab to treat subfoveal choroidal neovascularisation can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
